EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparative effects of calcitriol and calcimimetic on bone health in renal insufficiency

Juan Miguel Díaz-Tocados iD, María Encarnación Rodríguez-Ortiz iD, Carmen Herencia, Rodrigo López-Baltanás, Daniel Jurado-Montoya, Raquel María García-Saez iD, Karen Valdés-Díaz, Julio Manuel Martínez-Moreno iD, Rafael Santamaría iD, María Victoria Pendón-Ruiz de Mier, Cristian Rodelo-Haad iD, João Miguel Frazão und 4 weitere

The FASEB Journal · 2024

DOI: 10.1096/fj.202302704r ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The FASEB Journal, 2024. Verfasst von Juan Miguel Díaz-Tocados und 15 weiteren Autor:innen. Beteiligte Einrichtung: Vascular and Renal Translational Research Group, Biomedical Research Institute of Lleida - Dr. Pifarré Foundation (IRBLleida), Lleida, Spain. Hauptthemen laut MEDLINE: Calcitriol, Calcimimetic Agents, Parathyroid Hormone, Osteoblasts. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MEC | Instituto de Salud Carlos III (ISCIII), European Uremic Toxins Work Group of the ESAO (European Society of Artificial Organs), Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Calcitriol and calcimimetics are used to treat hyperparathyroidism secondary to chronic kidney disease (CKD). Calcitriol administration and the subsequent increase in serum calcium concentration decrease parathyroid hormone (PTH) levels, which should reduce bone remodeling. We have previously reported that, when maintaining a given concentration of PTH, the addition of calcimimetics is associated with an increased bone cell activity. Whether calcitriol administration affects bone cell activity while PTH is maintained constant should be evaluated in an animal model of renal osteodystrophy. The aim of the present study was to compare in CKD PTH‐clamped rats the bone effects of calcitriol and calcimimetic administration. The results show that the administration of calcitriol and calcimimetic at doses that induced a similar reduction in PTH secretion produced dissimilar effects on osteoblast activity in 5/6 nephrectomized (Nx) rats with secondary hyperparathyroidism and in Nx rats with clamped PTH. Remarkably, in both rat models, the administration of calcitriol decreased osteoblastic activity, whereas calcimimetic increased bone cell activity. In vitro, calcitriol supplementation inhibited nuclear translocation of β‐catenin and reduced proliferation, osteogenesis, and mineralization in mesenchymal stem cells differentiated into osteoblasts. In conclusion, besides the action of calcitriol and calcimimetics at parathyroid level, these treatments have specific effects on bone cells that are independent of the PTH level.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CalcitriolCalcimimetic AgentsParathyroid HormoneOsteoblastsAnimalsRatsMaleHyperparathyroidism, SecondaryBone and BonesRats, WistarRenal InsufficiencyOsteogenesisRenal Insufficiency, ChronicCell DifferentiationCalcium

Stichwörter der Autor:innen

bone histomorphometrycalcimimeticcalcitriolrenal osteodystrophysecondary hyperparathyroidism

Substanzen

CalcitriolCalcimimetic AgentsParathyroid HormoneCalcium

Autor:innen und Institutionen

  • Vascular and Renal Translational Research Group, Biomedical Research Institute of Lleida - Dr. Pifarré Foundation (IRBLleida), Lleida, Spain.
  • Calcium Metabolism and Vascular Calcification Unit, Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain.
  • Deparment of Medicine, University of Cordoba, Cordoba, Spain.
  • Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS2040), Madrid, Spain.
  • Nephrology Service, Reina Sofia University Hospital, Cordoba, Spain.
  • Renal, Vascular and Diabetes Research Laboratory, Jiménez Díaz Foundation University Hospital and Health Research Institute, Autonomous University of Madrid, Madrid, Spain.

ORCID-Profile: Juan Miguel Díaz-Tocados, María Encarnación Rodríguez-Ortiz, Raquel María García-Saez, Julio Manuel Martínez-Moreno, Rafael Santamaría, Cristian Rodelo-Haad, Mariano Rodríguez, Juan Rafael Muñoz-Castañeda

Förderung

  • MEC | Instituto de Salud Carlos III (ISCIII)
  • European Uremic Toxins Work Group of the ESAO (European Society of Artificial Organs)
  • Instituto de Salud Carlos III

Zitieren

APA

Díaz-Tocados, J. M., Rodríguez-Ortiz, M. E., Herencia, C., López-Baltanás, R., Jurado-Montoya, D., García-Saez, R. M., Valdés-Díaz, K., Martínez-Moreno, J. M., Santamaría, R., Pendón-Ruiz de Mier, M. V., Rodelo-Haad, C., Frazão, J. M., Felsenfeld, A. J., Rodríguez, M., Almadén, Y., & Muñoz-Castañeda, J. R. (2024). Comparative effects of calcitriol and calcimimetic on bone health in renal insufficiency. The FASEB Journal. https://doi.org/10.1096/fj.202302704r

Vancouver

Díaz-Tocados JM, Rodríguez-Ortiz ME, Herencia C, López-Baltanás R, Jurado-Montoya D, García-Saez RM, et al. Comparative effects of calcitriol and calcimimetic on bone health in renal insufficiency. The FASEB Journal. 2024. doi:10.1096/fj.202302704r

BibTeX
@article{DazTocados2024,
  author = {Díaz-Tocados, Juan Miguel and Rodríguez-Ortiz, María Encarnación and Herencia, Carmen and López-Baltanás, Rodrigo and Jurado-Montoya, Daniel and García-Saez, Raquel María and Valdés-Díaz, Karen and Martínez-Moreno, Julio Manuel and Santamaría, Rafael and Pendón-Ruiz de Mier, María Victoria and Rodelo-Haad, Cristian and Frazão, João Miguel and Felsenfeld, Arnold J and Rodríguez, Mariano and Almadén, Yolanda and Muñoz-Castañeda, Juan Rafael},
  title = {Comparative effects of calcitriol and calcimimetic on bone health in renal insufficiency},
  journal = {The FASEB Journal},
  year = {2024},
  doi = {10.1096/fj.202302704r}
}
Kostenlos starten →